论文部分内容阅读
目的:探讨糖尿病肾病患者血浆基质金属蛋白酶-2和同型半胱氨酸水平及其临床意义。方法:选取糖尿病患者71例,其中并发糖尿病肾病组(n=35)和未并发肾病组(n=36),同时选取健康人群40例为对照组。检测患者MMP-2、Hcy、MAU及Scr水平。结果:糖尿病肾病组、糖尿病无肾病组血浆MMP-2、Hcy及MAU水平均显著高于健康对照组(P<0.01);与糖尿病无肾病组比较,糖尿病肾病组患者MMP-2、Hcy及MAU水平较高(P<0.05);糖尿病肾病组患者的血浆SCr水平明显高于其他两组(P<0.05)。糖尿病肾病患者血浆MMP-2与MAU呈显著正相关(r=0.522,P<0.05),与Hcy呈显著负相关(r=-0.007,P<0.05),与Scr不相关(P>0.05);Hcy与MAU(r=0.012,P<0.05)、Scr均(r=0.031,P<0.05)呈正相关。结论:糖尿病肾病患者MMP-2水平降低,Hcy水平升高,有望作为糖尿病肾病患者的诊断和预后预测参考指标。
Objective: To investigate the plasma levels of matrix metalloproteinase-2 and homocysteine in patients with diabetic nephropathy and its clinical significance. Methods: Totally 71 diabetic patients were enrolled, including diabetic nephropathy group (n = 35) and non-concurrent nephropathy group (n = 36). Forty healthy people were selected as control group. The levels of MMP-2, Hcy, MAU and Scr in the patients were detected. Results: The levels of MMP-2, Hcy and MAU in diabetic nephropathy group and diabetic nephropathy group were significantly higher than those in healthy control group (P <0.01). Compared with diabetic nephropathy group, the levels of MMP-2, Hcy and MAU (P <0.05). The level of plasma SCr in patients with diabetic nephropathy was significantly higher than that in the other two groups (P <0.05). There was a significant positive correlation between plasma MMP - 2 and MAU in patients with diabetic nephropathy (r = 0.522, P <0.05) and negative correlation with Hcy (r = -0.007, P <0.05), but not with Scr (P> 0.05). There was a positive correlation between Hcy and MAU (r = 0.012, P <0.05) and Scr (r = 0.031, P <0.05). Conclusion: The level of MMP-2 and Hcy in patients with diabetic nephropathy is lower than that in patients with diabetic nephropathy, which is expected to serve as a reference index for the diagnosis and prognosis prediction of patients with diabetic nephropathy.